- Global Pharma News & Resources

ReForm Biologics Announces the Issuance of Chinese Patent for Therapeutic Protein Formulations

ReForm Biologics Expands Its Intellectual Property Estate to Improve Patient Care

WOBURN, Mass.--(BUSINESS WIRE)--ReForm Biologics, a company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, announced the expansion of its patent portfolio with issuance of its first patent in China, Patent No. CN ZL20158003.

The patent, entitled “Viscosity-Reducing Excipient Compounds for Protein Formulations,” covers formulations containing caffeine as an excipient that significantly reduces the viscosity of highly concentrated therapeutic protein solutions. ReForm has protected caffeine as a viscosity reducing excipient in four previous patents, U.S. Patent No. 9,605,051, U.S. Patent No. 9,867,881, U.S. Patent No. 10,478,498 and Japanese Patent No. JP 6674910.

“With our recent announcement that ReForm Biologics is developing an in-house bio-innovative medicine pipeline to convert hospital-based intravenous dosing to subcutaneous injections, this patent will allow the potential development of new treatments in China,” said John M. Sorvillo, Ph.D., Chief Executive Officer. “Our strategy is focused on improving patient compliance, convenience, flexibility, and ultimately reducing patient pain and suffering. We believe that this approach could facilitate partnerships with pharmaceutical companies in the rapidly expanding Chinese life sciences sector.”

“The ability to deliver highly concentrated, protein formulations still remains a major challenge for biopharmaceutical companies,” said Robert Mahoney, Ph.D., Vice President R&D. “This new patent in China expands the reach of our innovative platform that can enhance new biologic therapeutics, including pediatric applications, by reducing injection volumes, pain and discomfort, allowing for better patient care.”

About ReForm Biologics

ReForm Biologics creates gentler therapies for fragile patients, including pediatric patients, by using our proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. Our goal is to enhance comfort, convenience, safety and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. For more information, visit


Press Contact
Rob Kloppenburg
Shoreline Biotech Communications
(617) 930-5595

Editor Details

  • Company:
    • Businesswire
Last Updated: 08-Mar-2021